[Insert Figure 1 here]
Because psychiatric populations are difficult to access, recruit and retain in research studies we must leverage all data points including findings from the subclinical population. We subscribe to the view that the general population falls along a spectrum of schizotypal symptoms (theoretical review in (Grant et al., 2018); see Figure 2 for illustration). People with more symptoms, but within neurotypical range, are referred to as having ‘high schizotypy’. First degree relatives of those with schizophrenia typically have high schizotypy ratings, and are considered to be at high clinical risk (Kalmady et al., 2020; Le et al., 2020). As noted, studies in first degree relatives and in neurotypical individuals with high schizotypy scores avoid complications and confounds such as medication type, dosage, duration, and mental health comorbidities. An important challenge in subclinical populations is that any biomarker would be weaker. We began our review by searching specific sensory and working memory terms in PubMed and counting the number of studies identified; see Table 1. We then summarize the reports of abnormal auditory and visual SM in SSD and turn to WM before discussing whether empirically derived biomarkers can serve as indicators of clinical remediation.